Needham Maintains Buy on Revolution Medicines, Raises Price Target to $235
Needham raises price target on Revolution Medicines to $235
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ: RVMD ) with a Buy and raises the price target from $183 to $235.